{"meta":{"query_hash":"55e85dd4d3d6","filters":{"venue":"Oncology and Therapy"},"cohort_total":22,"direct_labels_cover":0,"predictions_cover":22,"exported":22,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/55e85dd4d3d6","api":"https://metacan.xera.ac/api/v1/cohort?venue=Oncology+and+Therapy"},"results":[{"id":"W2526572293","doi":"10.1007/s40487-016-0030-2","title":"Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma","year":2016,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dabrafenib; Trametinib; Vemurafenib; Ipilimumab; Medicine; Dacarbazine; Internal medicine; Oncology; Hazard ratio; Progression-free survival; Melanoma; Confidence interval; Metastatic melanoma; Cancer research; Chemotherapy; Cancer; Biology; Immunotherapy; MAPK/ERK pathway","score_opus":0.05188755218340509,"score_gpt":0.320069913384466,"score_spread":0.2681823612010609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526572293","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10216004,0.87396663,0.010635802,0.0029776033,0.00068050815,0.00048517936,0.005726351,0.00020370445,0.003164174],"genre_scores_gemma":[0.88654774,0.10242046,0.005847198,0.0010200884,0.00029735343,0.0005526141,0.002576546,0.00006468435,0.0006733319],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9848681,0.012115331,0.00083821133,0.0010816255,0.0008484382,0.00024835748],"domain_scores_gemma":[0.9800679,0.015850147,0.0021457686,0.0008597841,0.00081917056,0.00025731814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023915157,0.0020105946,0.0063521806,0.0035895274,0.0003837241,0.0023422162,0.0014763788,0.001386027,0.0028111662],"category_scores_gemma":[0.036788132,0.0008156523,0.03420115,0.0030971281,0.00038444359,0.00092331076,0.0008098446,0.0017529484,0.00017436019],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060345735,0.000045965477,0.020250008,0.020826804,0.9220338,0.00012998666,0.000035059114,0.014953665,0.00027697106,0.00047607426,0.001105832,0.013831363],"study_design_scores_gemma":[0.0013808552,0.00040335837,0.013464643,0.002541756,0.97143406,0.00012184023,0.000022930486,0.006506418,0.00022029532,0.0013762721,0.0024967494,0.00003094153],"about_ca_topic_score_codex":0.018707126,"about_ca_topic_score_gemma":0.02298327,"teacher_disagreement_score":0.023915157,"about_ca_system_score_codex":0.0033183598,"about_ca_system_score_gemma":0.002561308,"threshold_uncertainty_score":0.12647694},"labels":[],"label_agreement":null},{"id":"W2793685398","doi":"10.1007/s40487-018-0056-8","title":"Uveal Melanoma: A Review of the Literature","year":2018,"lang":"en","type":"review","venue":"Oncology and Therapy","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Melanoma; Medicine; Enucleation; Uvea; Metastasis; Dermatology; Disease; Ocular Melanoma; Pathology; Cancer; Internal medicine; Surgery; Cancer research","score_opus":0.039370848623730095,"score_gpt":0.39129297175629807,"score_spread":0.351922123132568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793685398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015658609,0.9990613,0.000028531082,0.00015730347,0.00013321785,0.0000036805368,0.000028534565,0.0000041669205,0.00042671934],"genre_scores_gemma":[0.0010142601,0.9982529,0.00011301311,0.0001626005,0.00022689108,0.000004473299,0.000043545762,9.963818e-7,0.00018122194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997129,0.000039278442,0.0000938503,0.000051293035,0.00007931778,0.000023306422],"domain_scores_gemma":[0.99890566,0.00056195236,0.0002491736,0.000023534934,0.00018674295,0.000072895775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049777067,0.00091201527,0.0014462927,0.008084559,0.00055448787,0.0012354472,0.0010575046,0.00091817084,0.0062902058],"category_scores_gemma":[0.0016819118,0.0003748687,0.0007296069,0.006694354,0.00047888234,0.0019924622,0.0006748572,0.0011672109,0.0014936997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121815014,0.000092810646,0.0012463215,0.110057496,0.00026422,0.002344764,0.00032975274,0.00034613005,0.0011025396,0.0017786239,0.0664247,0.8158908],"study_design_scores_gemma":[0.000030142257,0.00013377135,0.0045299046,0.04790962,0.0008910579,0.021875821,0.0003849794,0.00010469836,0.0003210964,0.002229278,0.92153996,0.000049760867],"about_ca_topic_score_codex":0.0017843846,"about_ca_topic_score_gemma":0.0031466838,"teacher_disagreement_score":0.008084559,"about_ca_system_score_codex":0.0005912745,"about_ca_system_score_gemma":0.0018221153,"threshold_uncertainty_score":0.021042824},"labels":[],"label_agreement":null},{"id":"W2896198794","doi":"10.1007/s40487-018-0065-7","title":"Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","year":2018,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Cancer survivorship and care","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ontario Institute for Cancer Research; Cancer Care Ontario","keywords":"Common Terminology Criteria for Adverse Events; Medicine; Documentation; Adverse effect; MEDLINE; Ambulatory; Patient satisfaction; Family medicine; Surgery; Internal medicine","score_opus":0.03526889379340401,"score_gpt":0.35689994923705654,"score_spread":0.3216310554436525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896198794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.920554,0.010069218,0.01254926,0.002735409,0.00019464851,0.0054714913,0.03470134,0.00056489476,0.013159748],"genre_scores_gemma":[0.9684383,0.0024494487,0.011876432,0.0007314876,0.00013059765,0.002844223,0.012706597,0.000036462185,0.00078638014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9846154,0.0074544484,0.003967354,0.0011523713,0.0024359957,0.00037439412],"domain_scores_gemma":[0.91496027,0.012519171,0.058939088,0.002952025,0.0087036425,0.001925904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011835546,0.00038002164,0.0008111534,0.0027247001,0.00032656745,0.00086996285,0.00063355005,0.00040644113,0.0015150721],"category_scores_gemma":[0.03373057,0.00016528311,0.0007202825,0.003540935,0.00034677703,0.00093190314,0.0009391583,0.00078256615,0.0004038827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053300493,0.00018491899,0.9374968,0.0007723435,0.0002133833,0.000053852742,0.00031372494,0.00036096745,0.00047945604,0.00012511038,0.0052532153,0.05421316],"study_design_scores_gemma":[0.00010163397,0.0008757574,0.99200714,0.00024148855,0.00009714236,0.00032610237,0.000196728,0.0008816889,0.000633849,0.00012346232,0.0044871955,0.00002772975],"about_ca_topic_score_codex":0.002575516,"about_ca_topic_score_gemma":0.0040993975,"teacher_disagreement_score":0.011835546,"about_ca_system_score_codex":0.0007221995,"about_ca_system_score_gemma":0.0016288141,"threshold_uncertainty_score":0.0625931},"labels":[],"label_agreement":null},{"id":"W2911783086","doi":"10.1007/s40487-019-0093-y","title":"Correction to: Uveal Melanoma: A Review of the Literature","year":2019,"lang":"en","type":"review","venue":"Oncology and Therapy","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Melanoma; Information retrieval; Computer science; Medicine; History; Cancer research","score_opus":0.03696998735483649,"score_gpt":0.38780590185358327,"score_spread":0.3508359144987468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911783086","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000309866,0.04755199,0.0005578482,0.05415799,0.89407796,0.000027699642,0.00050614955,0.00014769542,0.0026627628],"genre_scores_gemma":[0.017338252,0.24052653,0.0035611542,0.0918224,0.57654655,0.00015060659,0.0018802079,0.00077614735,0.06739817],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99715877,0.00048408096,0.0007509321,0.0003508422,0.0009855663,0.000269876],"domain_scores_gemma":[0.9810879,0.0041999537,0.0016570531,0.0005463428,0.011511435,0.0009973843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031995284,0.0011522719,0.001672243,0.0053444775,0.0014633086,0.0027577393,0.0020983208,0.0026101735,0.03852288],"category_scores_gemma":[0.034603655,0.00048261802,0.001294672,0.0033796222,0.0015280931,0.002399301,0.0018756337,0.0044786646,0.021365035],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004448348,0.00000648298,0.0001441992,0.0017348792,0.000028341809,0.00069519033,0.00007054427,0.00003798931,0.00011139292,0.0005921461,0.95774937,0.03878487],"study_design_scores_gemma":[0.000024182413,0.000026056812,0.0005003261,0.0024625494,0.00007326257,0.0031927838,0.00010458052,0.00006461504,0.00022041501,0.00073552295,0.99256706,0.000028689406],"about_ca_topic_score_codex":0.0042237425,"about_ca_topic_score_gemma":0.006509951,"teacher_disagreement_score":0.03852288,"about_ca_system_score_codex":0.0016307825,"about_ca_system_score_gemma":0.004856576,"threshold_uncertainty_score":0.12887186},"labels":[],"label_agreement":null},{"id":"W3124101675","doi":"10.1007/s40487-020-00135-z","title":"Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature","year":2021,"lang":"en","type":"review","venue":"Oncology and Therapy","topic":"Genital Health and Disease","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Penile cancer; Medicine; Disease; Intensive care medicine; Multidisciplinary approach; Human papilloma virus; Cancer; Clinical trial; Internal medicine; Cervical cancer","score_opus":0.06502141781225386,"score_gpt":0.44325937406545457,"score_spread":0.3782379562532007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124101675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000095099116,0.9990914,0.000060281447,0.00025266752,0.000113283575,0.0000028131776,0.000017755565,0.000004302317,0.0003623811],"genre_scores_gemma":[0.00046534883,0.99895835,0.00012098212,0.0001696919,0.00015611268,0.0000030329827,0.000023725208,9.433344e-7,0.00010187346],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997497,0.00005212049,0.000062354484,0.00004495733,0.00007183873,0.00001899937],"domain_scores_gemma":[0.99897194,0.00064849935,0.0001533036,0.000017219605,0.00015845003,0.000050570656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006169613,0.00072735624,0.0013082549,0.0028624486,0.00033221827,0.0010627513,0.0008568031,0.0007782339,0.0049492465],"category_scores_gemma":[0.0019101197,0.00024505012,0.0006543607,0.003314254,0.00036143066,0.0013495339,0.00060045713,0.0012117294,0.0012552878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006935443,0.000047413705,0.0003248954,0.04972359,0.00013479523,0.00035512255,0.000103450395,0.000356011,0.00046960235,0.0011423588,0.027964525,0.9193089],"study_design_scores_gemma":[0.000024469631,0.00015547652,0.0019543446,0.03462696,0.00068193517,0.0058680875,0.0002129011,0.00015196027,0.00027026157,0.0019116019,0.9541017,0.0000403043],"about_ca_topic_score_codex":0.00097088254,"about_ca_topic_score_gemma":0.0021107874,"teacher_disagreement_score":0.0049492465,"about_ca_system_score_codex":0.0005056385,"about_ca_system_score_gemma":0.0012204918,"threshold_uncertainty_score":0.016556859},"labels":[],"label_agreement":null},{"id":"W4214763123","doi":"10.1007/s40487-022-00187-3","title":"Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada","year":2022,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Amgen (Canada); University of Calgary","funders":"Parexel; Amgen","keywords":"Reimbursement; Medicine; Context (archaeology); Lung cancer; Medical prescription; Family medicine; Health care; Oncology; Geography; Economic growth; Pharmacology; Economics","score_opus":0.23925194046491302,"score_gpt":0.47329611718186954,"score_spread":0.23404417671695651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214763123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9229208,0.0051731034,0.0038581225,0.0045035146,0.000056128927,0.0004055568,0.05509745,0.00013884611,0.007846501],"genre_scores_gemma":[0.984568,0.0013403976,0.0025853775,0.00030777208,0.00002306834,0.000104850085,0.010296919,0.000015266913,0.00075827143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954953,0.0010924281,0.00045066103,0.00075292046,0.0013390774,0.00086952135],"domain_scores_gemma":[0.96363574,0.014171193,0.009981021,0.0008381178,0.009453933,0.0019201125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057918495,0.00080915197,0.00072695914,0.0038251556,0.00097598345,0.0023652406,0.0016756409,0.0007641252,0.0022059043],"category_scores_gemma":[0.035669185,0.00050287065,0.0022771487,0.008078057,0.00066885084,0.0008339484,0.0013490379,0.0014132108,0.00022457328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003827754,0.00011077848,0.9019173,0.00031751388,0.0010723725,0.00014162298,0.00016719634,0.072834164,0.000095384064,0.0013167189,0.0045734295,0.017070787],"study_design_scores_gemma":[0.00020836043,0.00028270538,0.79473567,0.0003363192,0.0012578614,0.00016255317,0.0007554276,0.19404007,0.00047814575,0.0014666652,0.0061615617,0.00011467987],"about_ca_topic_score_codex":0.9848638,"about_ca_topic_score_gemma":0.9714065,"teacher_disagreement_score":0.0655003,"about_ca_system_score_codex":0.0655003,"about_ca_system_score_gemma":0.05908613,"threshold_uncertainty_score":0.4752401},"labels":[],"label_agreement":null},{"id":"W4220883998","doi":"10.1007/s40487-022-00193-5","title":"Stapler-Assisted Pharyngeal Closure After Total Laryngectomy: A Systematic Review and Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Oncology and Therapy","topic":"Reconstructive Surgery and Microvascular Techniques","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Laryngectomy; Closure (psychology); Medicine; Meta-analysis; Surgery; Larynx; Internal medicine; Political science","score_opus":0.09282302367174915,"score_gpt":0.37923829548651233,"score_spread":0.2864152718147632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220883998","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002813525,0.9962845,0.00013139483,0.000102649225,0.00005918205,0.00007296163,0.00034954114,0.0000065554023,0.00017973233],"genre_scores_gemma":[0.06782316,0.93012893,0.00060701027,0.00038505255,0.00013822975,0.0002947779,0.00045983164,0.000008337846,0.00015456583],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99656963,0.0013288733,0.0010773712,0.0004286353,0.00046188477,0.00013353185],"domain_scores_gemma":[0.98855525,0.008515216,0.0018155169,0.00021631311,0.0007572257,0.000140371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00517062,0.0013208456,0.009506797,0.0037657572,0.00042836013,0.0018993203,0.0014265636,0.0014438522,0.0037638005],"category_scores_gemma":[0.016118376,0.00071649696,0.013586822,0.0058543854,0.0004611267,0.0010064658,0.00069814525,0.0010155917,0.00024085381],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012213681,0.000039682338,0.0053691994,0.7938502,0.17201261,0.00017096884,0.000089136716,0.0003397266,0.00021284093,0.00015543659,0.0013467281,0.025192158],"study_design_scores_gemma":[0.00069630693,0.00044335137,0.015570575,0.12577091,0.84894854,0.00037739982,0.00011774403,0.0002673854,0.0002272491,0.00030776166,0.0072299894,0.000042734853],"about_ca_topic_score_codex":0.0048466516,"about_ca_topic_score_gemma":0.011694691,"teacher_disagreement_score":0.009506797,"about_ca_system_score_codex":0.0012991999,"about_ca_system_score_gemma":0.0028293098,"threshold_uncertainty_score":0.02734512},"labels":[],"label_agreement":null},{"id":"W4282542898","doi":"10.1007/s40487-022-00200-9","title":"Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making","year":2022,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Pfizer (Canada)","funders":"Pfizer Canada; Astellas Pharma; Flatiron Health; Springworks Therapeutics; Agios Pharmaceuticals; Jazz Pharmaceuticals; Celgene; AstraZeneca; National Institute of Nursing Research; Daiichi-Sankyo; Amgen; Pfizer; National Institutes of Health; Helsinn","keywords":"Medicine; Qualitative research; Quality of life (healthcare); Family medicine; Stakeholder; Perspective (graphical); Intensive care medicine; Nursing; Public relations","score_opus":0.023188599716836088,"score_gpt":0.3436971896524644,"score_spread":0.3205085899356283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282542898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770727,0.002099563,0.001570715,0.009388998,0.00014119038,0.0000802713,0.00012028838,0.000019579877,0.009506638],"genre_scores_gemma":[0.99731976,0.0005747051,0.00039974548,0.0009966331,0.000018016246,0.000028976194,0.000023055047,0.0000050283875,0.0006340156],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.98759544,0.010595411,0.0003047135,0.00030818427,0.00052807416,0.0006682458],"domain_scores_gemma":[0.9786986,0.016530933,0.0018160595,0.00022248141,0.00096469687,0.0017671367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009197687,0.00027970757,0.00033800313,0.0004713927,0.0052628415,0.0028848164,0.0007003903,0.0014813521,0.0039202883],"category_scores_gemma":[0.02022789,0.00027345927,0.00043538545,0.0004659227,0.004638516,0.0026102741,0.0031718127,0.0023974117,0.0002729698],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009270809,0.000049631588,0.007460883,0.00020492593,0.000016782697,0.0012024677,0.98107255,0.00012557827,0.00043818,0.0010222023,0.0012768547,0.0070371088],"study_design_scores_gemma":[0.000017819557,0.00012012765,0.0037609574,0.00027627684,0.000016279806,0.0013907045,0.97726464,0.0001601614,0.0002836638,0.00066549325,0.016009163,0.000034732697],"about_ca_topic_score_codex":0.0074398285,"about_ca_topic_score_gemma":0.00825371,"teacher_disagreement_score":0.009197687,"about_ca_system_score_codex":0.0028725637,"about_ca_system_score_gemma":0.0035460652,"threshold_uncertainty_score":0.048642576},"labels":[],"label_agreement":null},{"id":"W4324129452","doi":"10.1007/s40487-023-00224-9","title":"Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Oncology and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Malignancy; Adverse effect; Cancer; Oncology; Narrative review; Adjuvant; Internal medicine; Metastatic breast cancer; Immune system; Intensive care medicine; Immunology","score_opus":0.054315171648327346,"score_gpt":0.4046859411102719,"score_spread":0.35037076946194456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324129452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005827263,0.9993086,0.000024876199,0.00016096636,0.00010342432,0.0000061327246,0.000023708008,0.000002467787,0.00031156532],"genre_scores_gemma":[0.00039527324,0.9991425,0.000064336156,0.00016281217,0.00008535658,0.000005962986,0.000024895939,5.9966055e-7,0.00011822639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996983,0.00006066471,0.00008216692,0.000045049866,0.000093312556,0.000020568721],"domain_scores_gemma":[0.99896455,0.0006563704,0.00018588595,0.00001610478,0.00014743982,0.000029697196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006632361,0.0007215834,0.0013702105,0.002725155,0.00028838476,0.0010807094,0.0007899115,0.00086950825,0.005204507],"category_scores_gemma":[0.0022694492,0.00024596255,0.0010769059,0.0027944432,0.00023422536,0.0010183089,0.00060340535,0.0011067494,0.00092252553],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011705261,0.00005667619,0.0003049023,0.20414607,0.00048332097,0.00025045156,0.00012673243,0.00028293068,0.0005696879,0.00196097,0.04270582,0.74899536],"study_design_scores_gemma":[0.000044519296,0.0001441882,0.0016650361,0.13021038,0.0019722865,0.0026396126,0.0001378455,0.00011995841,0.00025663275,0.0015233855,0.8612566,0.0000296086],"about_ca_topic_score_codex":0.0016158281,"about_ca_topic_score_gemma":0.0035248369,"teacher_disagreement_score":0.005204507,"about_ca_system_score_codex":0.0005517246,"about_ca_system_score_gemma":0.0019109589,"threshold_uncertainty_score":0.017410755},"labels":[],"label_agreement":null},{"id":"W4389454730","doi":"10.1007/s40487-023-00253-4","title":"Experiences and Support Needs of Caregivers of Patients with Higher-Risk Myelodysplastic Syndrome via Online Bulletin Board in the USA, Canada and UK","year":2023,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharma; Novartis","keywords":"Myelodysplastic syndromes; Medicine; Family medicine; Disease; Gerontology; Internal medicine","score_opus":0.01175460647217719,"score_gpt":0.26545001392252043,"score_spread":0.25369540745034325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389454730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922959,0.0010135276,0.000110950656,0.0031271114,0.00007617924,0.0000509563,0.00023077331,0.000007742638,0.0030868282],"genre_scores_gemma":[0.9970505,0.0008261744,0.00013866085,0.0009517945,0.00001194312,0.000042210442,0.0000903233,0.000005740622,0.0008826657],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.997872,0.0009661436,0.00010730031,0.00010373296,0.00026927487,0.0006815068],"domain_scores_gemma":[0.99170494,0.0021210196,0.001029748,0.000106769556,0.001902708,0.0031348043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020133234,0.00026596946,0.00047476104,0.00074238685,0.0075917128,0.0026077826,0.0005680405,0.00063516153,0.0029781528],"category_scores_gemma":[0.0096166525,0.00023446286,0.0002107299,0.0012329844,0.0025074065,0.0012843075,0.0029436564,0.0012955416,0.00019273293],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002261285,0.000096638214,0.13348393,0.00035435634,0.000016174807,0.0024136812,0.82962483,0.00007351413,0.00040910358,0.0007539565,0.008849832,0.02369778],"study_design_scores_gemma":[0.000011035537,0.00006350428,0.038787346,0.00034326327,0.000008754698,0.00045371006,0.94682145,0.0000739194,0.000086074324,0.00008999804,0.013230874,0.000029988174],"about_ca_topic_score_codex":0.5938915,"about_ca_topic_score_gemma":0.71654034,"teacher_disagreement_score":0.5938915,"about_ca_system_score_codex":0.013587882,"about_ca_system_score_gemma":0.023746092,"threshold_uncertainty_score":0.81700027},"labels":[],"label_agreement":null},{"id":"W4391881791","doi":"10.1007/s40487-024-00264-9","title":"Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies","year":2024,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"Wellcome Trust; F. Hoffmann-La Roche","keywords":"Breast cancer; Government revenue; Trastuzumab; Tax revenue; Economics; Revenue; Medicine; Cancer; Public economics; Internal medicine; Finance","score_opus":0.054900633213822006,"score_gpt":0.3224307863097,"score_spread":0.267530153095878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391881791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928396,0.0004942067,0.003457876,0.00040601534,0.000008157312,0.000104205275,0.00045222958,0.000008967849,0.002228769],"genre_scores_gemma":[0.99485105,0.00033207363,0.0036757865,0.000027603204,0.000008756562,0.000058124122,0.000258784,0.000006173279,0.00078168476],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99835604,0.0010804838,0.00006734489,0.00013866986,0.00012048891,0.00023692449],"domain_scores_gemma":[0.9883809,0.010141438,0.000658955,0.0002277999,0.00035004065,0.00024078944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043195025,0.00069927954,0.0005944383,0.0011507889,0.00074746856,0.001950602,0.0012706696,0.0019966776,0.0023242834],"category_scores_gemma":[0.0110524725,0.00050251535,0.0017009815,0.0019959023,0.0007115134,0.00088445214,0.0012318406,0.0014069002,0.00015468473],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012786336,0.0028258543,0.24143827,0.00041832935,0.00060242333,0.006048501,0.00082850124,0.70937216,0.0006218549,0.010985833,0.0018258421,0.023753788],"study_design_scores_gemma":[0.00037655153,0.0011410592,0.106656514,0.0001579962,0.0004386888,0.0013749764,0.0050011943,0.8743739,0.0015341135,0.005990529,0.0028429932,0.00011144591],"about_ca_topic_score_codex":0.13286598,"about_ca_topic_score_gemma":0.09634802,"teacher_disagreement_score":0.13286598,"about_ca_system_score_codex":0.006777236,"about_ca_system_score_gemma":0.002280516,"threshold_uncertainty_score":0.2641852},"labels":[],"label_agreement":null},{"id":"W4392795080","doi":"10.1007/s40487-024-00268-5","title":"Real-World Treatment Patterns and Survival Among Patients with Stage I–III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment","year":2024,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; AstraZeneca (Canada); Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; AstraZeneca Canada; GlaxoSmithKline; Amgen","keywords":"Medicine; Internal medicine; Population; Oncology; Stage (stratigraphy); Chemotherapy; Cancer; Lung cancer; Surgery","score_opus":0.014697322355602704,"score_gpt":0.2974800527551476,"score_spread":0.2827827303995449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392795080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980305,0.00017518917,0.00003608089,0.000102664206,0.0000037876314,0.000005787821,0.0013785539,0.0000019295542,0.00026554105],"genre_scores_gemma":[0.99897695,0.00006073239,0.000025146397,0.000024557581,0.0000037543439,0.000004182231,0.0008361283,5.9348787e-7,0.00006795805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958724,0.0000751683,0.000053516902,0.000113938455,0.00008471435,0.00008548828],"domain_scores_gemma":[0.9982651,0.0001454503,0.001073654,0.00007078906,0.00016846065,0.00027658374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004341837,0.00013025271,0.0001706961,0.00037194986,0.00040262836,0.0005988722,0.00037572611,0.00036198512,0.00128092],"category_scores_gemma":[0.0018709715,0.00013226742,0.00028594208,0.00095455203,0.00041630515,0.00041045083,0.00034627193,0.000431953,0.00017751529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025217721,0.0000063509506,0.9996563,0.0000032320634,0.000012071346,0.000009934533,0.000020563111,0.000020856161,0.000027540716,0.0000042759043,0.000043616797,0.00016993456],"study_design_scores_gemma":[0.0000022965623,0.00002711278,0.9996124,0.0000031349662,0.000005576032,0.00004662587,0.000113257716,0.00007540619,0.000012486391,0.000007630405,0.000092478294,0.0000016891322],"about_ca_topic_score_codex":0.10697041,"about_ca_topic_score_gemma":0.15108787,"teacher_disagreement_score":0.10697041,"about_ca_system_score_codex":0.0015184373,"about_ca_system_score_gemma":0.00124811,"threshold_uncertainty_score":0.21269554},"labels":[],"label_agreement":null},{"id":"W4394843319","doi":"10.1007/s40487-024-00276-5","title":"Correction: Real-World Treatment Patterns and Survival Among Patients with Stage I–III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment","year":2024,"lang":"en","type":"erratum","venue":"Oncology and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; AstraZeneca (Canada); Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Primary treatment; Medicine; Stage (stratigraphy); Squamous cell cancer; Lung cancer; Cancer treatment; Oncology; Surgery; Internal medicine; Cancer; Biology","score_opus":0.012918693792509484,"score_gpt":0.3077022416866206,"score_spread":0.2947835478941111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394843319","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001522321,0.00048643016,0.0002972388,0.049818236,0.94248366,0.00003299612,0.0052145696,0.00020365565,0.001310922],"genre_scores_gemma":[0.031567223,0.00817209,0.008676261,0.17386596,0.5330095,0.0010176895,0.019418754,0.0031007936,0.22117169],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9948695,0.0010867288,0.001202961,0.0006795003,0.0016854618,0.0004758847],"domain_scores_gemma":[0.94801956,0.015169656,0.002927828,0.0030109053,0.028230144,0.002641931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071780267,0.0025158417,0.002305303,0.0039115897,0.0025139053,0.0036967902,0.004015931,0.006415078,0.08158996],"category_scores_gemma":[0.13072562,0.001545334,0.0025923278,0.003755328,0.0015961918,0.0022871133,0.0019667242,0.010266577,0.02980109],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002963383,0.0000033258573,0.00014929438,0.00012204848,0.00001695431,0.00009347621,0.000012030172,0.0000320357,0.000008304163,0.00017092723,0.9976833,0.0016786379],"study_design_scores_gemma":[0.0004327056,0.00003839089,0.005423911,0.0017597243,0.00023284287,0.0010649608,0.00022444616,0.0006679584,0.00029675843,0.00195184,0.98778987,0.00011663218],"about_ca_topic_score_codex":0.04942474,"about_ca_topic_score_gemma":0.04988356,"teacher_disagreement_score":0.08158996,"about_ca_system_score_codex":0.004797468,"about_ca_system_score_gemma":0.010082711,"threshold_uncertainty_score":0.27294564},"labels":[],"label_agreement":null},{"id":"W4395464285","doi":"10.1007/s40487-024-00272-9","title":"Identification of a Patient Suitable for CAR-T Cell Therapy in the Outpatient Setting: A Vodcast and Case Example","year":2024,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Hospital","funders":"","keywords":"Medicine; Referral; Chimeric antigen receptor; CAR T-cell therapy; CD19; Patient education; Cytokine release syndrome; Intensive care medicine; Medical emergency; Immunotherapy; Internal medicine; Cancer; Family medicine; Immunology; Antigen","score_opus":0.046091410346501216,"score_gpt":0.3533299062937665,"score_spread":0.30723849594726527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395464285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84603775,0.008316015,0.013050472,0.06922789,0.002067801,0.00054541655,0.0006083584,0.0003004359,0.059845734],"genre_scores_gemma":[0.97454256,0.0036719071,0.006113018,0.007775225,0.0016992115,0.000062102314,0.00022235069,0.000092807204,0.005820957],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99950445,0.00009685643,0.00005066642,0.00006916738,0.00007616245,0.00020270975],"domain_scores_gemma":[0.9987778,0.00031966795,0.00016114188,0.00003167285,0.000084245345,0.0006254907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030495966,0.00080255297,0.00061457296,0.0012244269,0.002756909,0.0017027038,0.00083280564,0.0034280056,0.0030533734],"category_scores_gemma":[0.0030665465,0.0004018111,0.00080191315,0.001022153,0.00088518095,0.0014712744,0.0013409314,0.0046006846,0.0009011217],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003783403,0.00009923776,0.006357301,0.000036433656,0.0000048920097,0.98525435,0.0004160251,0.00012001209,0.0004267052,0.00077247433,0.0025481724,0.003926631],"study_design_scores_gemma":[0.0000063153498,0.000045000386,0.0019799152,0.000035831687,0.0000043300493,0.9945088,0.00061507936,0.00026667403,0.00018568635,0.00039846142,0.0019426655,0.000011242075],"about_ca_topic_score_codex":0.0030987316,"about_ca_topic_score_gemma":0.0069138366,"teacher_disagreement_score":0.0034280056,"about_ca_system_score_codex":0.001949648,"about_ca_system_score_gemma":0.00089185475,"threshold_uncertainty_score":0.0141457915},"labels":[],"label_agreement":null},{"id":"W4401113520","doi":"10.1007/s40487-024-00292-5","title":"Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC","year":2024,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Osimertinib; Medicine; Discontinuation; Oncology; Internal medicine; Lung cancer; Tolerability; Erlotinib; Regimen; Epidermal growth factor receptor; Cancer; Adverse effect","score_opus":0.016297307568909986,"score_gpt":0.3246357236851056,"score_spread":0.3083384161161956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401113520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706215,0.0007125419,0.000051513976,0.00020365954,0.000006935881,0.000012994574,0.0012596984,0.000003732233,0.00068670895],"genre_scores_gemma":[0.9985133,0.00029524983,0.000047357615,0.0000801012,0.00001636726,0.000012881466,0.0009146226,0.00000251497,0.00011746345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918705,0.00013905873,0.00018049232,0.00016485326,0.00017654189,0.00015202237],"domain_scores_gemma":[0.9966787,0.000410891,0.0023810014,0.00006535717,0.00015828997,0.00030581746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005576619,0.00012894538,0.00027043995,0.00083843427,0.00036434043,0.0006393754,0.00036744785,0.000388962,0.0016798434],"category_scores_gemma":[0.0029698717,0.00013183942,0.00055190915,0.0015235577,0.00019519338,0.0005013797,0.0005165275,0.0006837317,0.00024458632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000601238,0.000019274701,0.9980774,0.000014762959,0.000021581722,0.00011101624,0.000055225606,0.000044323,0.000049362152,0.00001622266,0.00017442918,0.0013562217],"study_design_scores_gemma":[0.0000034156872,0.000059720787,0.9983979,0.000027876365,0.000014361872,0.0005210761,0.00026218445,0.00023566656,0.00004793042,0.000021599053,0.0004040477,0.000004184074],"about_ca_topic_score_codex":0.009083565,"about_ca_topic_score_gemma":0.011907384,"teacher_disagreement_score":0.009083565,"about_ca_system_score_codex":0.00083752524,"about_ca_system_score_gemma":0.00067866925,"threshold_uncertainty_score":0.0180614},"labels":[],"label_agreement":null},{"id":"W4406073812","doi":"10.1007/s40487-024-00323-1","title":"Aggressive Subtypes of Laryngeal Chondrosarcoma and their Clinical Behavior: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Oncology and Therapy","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Laryngectomy; Chondrosarcoma; Cricoid cartilage; Surgery; Adjuvant therapy; Larynx; General surgery; Internal medicine; Chemotherapy","score_opus":0.06825644552588343,"score_gpt":0.4429915277639929,"score_spread":0.3747350822381095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406073812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021362198,0.99697626,0.00005748612,0.00010332759,0.0000411552,0.0000923041,0.00037615543,0.0000036110127,0.00021342964],"genre_scores_gemma":[0.016140178,0.9829488,0.00027789915,0.000136868,0.000039729788,0.00015040569,0.00021453423,0.0000016988054,0.00008980697],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9978721,0.0005540807,0.0008842059,0.00020372939,0.00041726363,0.00006860419],"domain_scores_gemma":[0.9897183,0.0065383506,0.002458163,0.00012394824,0.001008857,0.00015234412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024156028,0.00087314675,0.0046107117,0.0077973255,0.00034087835,0.0011706476,0.0009696059,0.00083990034,0.002624149],"category_scores_gemma":[0.012127235,0.00058281084,0.0029904936,0.011773864,0.0004752886,0.0010817307,0.0005842318,0.00035437976,0.0002545427],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031044547,0.00002477889,0.0063904505,0.87655497,0.011308499,0.00040946002,0.00026278154,0.00014837165,0.00026469384,0.000153774,0.0039342875,0.10023756],"study_design_scores_gemma":[0.0005927682,0.0005539843,0.049505312,0.74465144,0.14140871,0.0036393336,0.0008390316,0.00020217044,0.00040127715,0.0003835844,0.057738975,0.0000835692],"about_ca_topic_score_codex":0.006933636,"about_ca_topic_score_gemma":0.02584579,"teacher_disagreement_score":0.0077973255,"about_ca_system_score_codex":0.001387086,"about_ca_system_score_gemma":0.0051712305,"threshold_uncertainty_score":0.013786554},"labels":[],"label_agreement":null},{"id":"W4408885282","doi":"10.1007/s40487-025-00328-4","title":"A US Survey Across Seven Early-Stage Cancers Assessing the Humanistic Burden of Recurrence on Patients and Caregivers","year":2025,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Cancer survivorship and care","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); Heritage College","funders":"Merck","keywords":"Medicine; Quality of life (healthcare); Cancer; Stage (stratigraphy); Internal medicine; Disease; Oncology; Feeling; Nursing; Psychology","score_opus":0.03225054663697788,"score_gpt":0.3738300962716893,"score_spread":0.3415795496347114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408885282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970151,0.00022993941,0.000096450225,0.00013220437,0.0000048716065,0.00007540735,0.00153223,0.000005392912,0.0009084376],"genre_scores_gemma":[0.99689096,0.00036483078,0.00032856493,0.00015632268,0.0000062079043,0.00013545294,0.0018398317,0.0000022420436,0.00027552928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988889,0.0005201915,0.00022807861,0.000068444664,0.00017814641,0.00011630056],"domain_scores_gemma":[0.9966114,0.0005962186,0.0014888779,0.000113407885,0.00072048255,0.0004696871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018340792,0.00019700648,0.00030755007,0.000892508,0.00052960287,0.00041242523,0.00022206969,0.00023765204,0.00089222234],"category_scores_gemma":[0.0040637855,0.00019278954,0.00042479025,0.0014731131,0.00022093159,0.00043313036,0.00082799746,0.00046692372,0.0001405557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007534398,0.00008114425,0.99112743,0.00006093999,0.000041041196,0.000088202374,0.0012587083,0.000057237885,0.00012012614,0.00002496416,0.0011990119,0.0058658766],"study_design_scores_gemma":[0.000010262419,0.00016699948,0.99594903,0.000031961143,0.0000141829,0.00016374991,0.0021314742,0.00008854124,0.000052677577,0.000014370544,0.0013702939,0.0000063559373],"about_ca_topic_score_codex":0.017459344,"about_ca_topic_score_gemma":0.02583261,"teacher_disagreement_score":0.017459344,"about_ca_system_score_codex":0.000956344,"about_ca_system_score_gemma":0.00087200105,"threshold_uncertainty_score":0.034715414},"labels":[],"label_agreement":null},{"id":"W4409538399","doi":"10.1007/s40487-025-00334-6","title":"On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC","year":2025,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Daiichi Sankyo Europe; EMD Serono; EUSA Pharma; Astellas Pharma; Genentech; UroGen Pharma; Eisai; Ipsen; Mirati Therapeutics; Gilead Sciences; Merck KGaA; Advanced Accelerator Applications; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Multidisciplinary approach; Perspective (graphical); Medicine; Horizon; Intensive care medicine; Computer science; Sociology; Physics; Artificial intelligence; Astronomy; Social science","score_opus":0.005897211184523203,"score_gpt":0.262218595216976,"score_spread":0.2563213840324528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409538399","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005452669,0.070558175,0.0035788766,0.8985403,0.0083866855,0.000067798595,0.00011852577,0.00012136489,0.013175599],"genre_scores_gemma":[0.15203273,0.18013379,0.020132845,0.6046145,0.032645177,0.0004437477,0.0005464197,0.0002681139,0.009182661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934574,0.0033986731,0.00034277883,0.00046029434,0.0008645092,0.0014763643],"domain_scores_gemma":[0.9808287,0.0026825126,0.0012824596,0.00020767903,0.0026964145,0.012302258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008609783,0.00054399157,0.0008095788,0.000696671,0.002879684,0.0061377576,0.0014897812,0.0054328633,0.010206847],"category_scores_gemma":[0.013928532,0.00029291728,0.0011826217,0.00072615943,0.0018057346,0.0064709717,0.007716171,0.009541709,0.0019983982],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043052202,0.00049108017,0.0069310064,0.002787861,0.00021380442,0.0012285315,0.0045747766,0.001622538,0.0018629502,0.02045001,0.44074425,0.51866263],"study_design_scores_gemma":[0.00033222497,0.0012463486,0.010045716,0.011283139,0.00033736374,0.0016094586,0.014295894,0.0016079964,0.00079777837,0.044315584,0.9139291,0.00019932138],"about_ca_topic_score_codex":0.0025488264,"about_ca_topic_score_gemma":0.008875666,"teacher_disagreement_score":0.010206847,"about_ca_system_score_codex":0.0033589753,"about_ca_system_score_gemma":0.01599416,"threshold_uncertainty_score":0.04553342},"labels":[],"label_agreement":null},{"id":"W4411202089","doi":"10.1007/s40487-025-00350-6","title":"Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Lung cancer; Medicine; Oncology; Chemotherapy; Complete response; Internal medicine; Duration (music); Cancer; Immunotherapy","score_opus":0.028651675311576492,"score_gpt":0.36962959291600705,"score_spread":0.3409779176044306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411202089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99869007,0.00033588224,0.00007114365,0.000051821626,0.0000070858755,0.000019224648,0.0005979318,0.0000035776736,0.00022325145],"genre_scores_gemma":[0.99949443,0.00003498591,0.00004393727,0.000024462985,0.0000055058067,0.000027673706,0.00022042886,0.0000014385154,0.00014711592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989692,0.00037935883,0.00007956436,0.0003028926,0.0001410096,0.00012799168],"domain_scores_gemma":[0.99743646,0.0010692023,0.000892061,0.00015071557,0.00018523204,0.0002663917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021975562,0.00018916107,0.0003282915,0.00022958725,0.00027465413,0.00032535795,0.00033207863,0.00044862405,0.0022550786],"category_scores_gemma":[0.0054562334,0.0001515538,0.00069137017,0.0003151246,0.000108290515,0.0004049512,0.0003281895,0.0005186185,0.00020084823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008211261,0.000225747,0.98061967,0.000087870554,0.00038269575,0.000030349276,0.00017716603,0.0001414224,0.00059419405,0.000023244045,0.0003522801,0.009154013],"study_design_scores_gemma":[0.000091243346,0.0013223503,0.9973187,0.000019860572,0.00021770832,0.000046814042,0.000091221424,0.00035399394,0.00012617427,0.000022994436,0.00038372137,0.00000525681],"about_ca_topic_score_codex":0.0023592666,"about_ca_topic_score_gemma":0.0030796519,"teacher_disagreement_score":0.0023592666,"about_ca_system_score_codex":0.00035015173,"about_ca_system_score_gemma":0.00038978588,"threshold_uncertainty_score":0.011621892},"labels":[],"label_agreement":null},{"id":"W4412629771","doi":"10.1007/s40487-025-00357-z","title":"The Health Impact of Using Anti-PD-1 Agents to Treat Early-Stage Cancer in Belgium","year":2025,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Merck","keywords":"Stage (stratigraphy); Cancer; Medicine; Internal medicine; Biology","score_opus":0.04550332840947906,"score_gpt":0.4467312410999579,"score_spread":0.4012279126904788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412629771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99277604,0.0013836772,0.0014158953,0.0006577555,0.000017509401,0.0000359478,0.0017977303,0.000036432117,0.0018790634],"genre_scores_gemma":[0.9983297,0.00026988515,0.0005742483,0.000086058666,0.0000027892638,0.000018784172,0.00041272014,0.0000062237864,0.00029972589],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99862885,0.0009476116,0.000034656274,0.00010813568,0.000079406054,0.00020138294],"domain_scores_gemma":[0.99896204,0.0005228997,0.00024541238,0.00002754446,0.00009457836,0.00014750329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016450821,0.00029699106,0.000404414,0.0003116056,0.00021379314,0.00084773335,0.000385214,0.00041158375,0.0015602071],"category_scores_gemma":[0.0029274456,0.00022327583,0.0010517671,0.00047249236,0.00027341835,0.00023078997,0.00050833577,0.00049092196,0.00008469046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073365155,0.00077959464,0.34910452,0.0006790984,0.0024616658,0.00083709514,0.0004518239,0.5710177,0.0031274238,0.0040226695,0.0036449146,0.05653695],"study_design_scores_gemma":[0.0018113252,0.0036548064,0.64754313,0.0005122394,0.0019903753,0.0011514626,0.0011372692,0.3186286,0.0038509166,0.004324626,0.015267249,0.00012788795],"about_ca_topic_score_codex":0.22844239,"about_ca_topic_score_gemma":0.14697932,"teacher_disagreement_score":0.22844239,"about_ca_system_score_codex":0.0068347766,"about_ca_system_score_gemma":0.004726314,"threshold_uncertainty_score":0.45422536},"labels":[],"label_agreement":null},{"id":"W4414120871","doi":"10.1007/s40487-025-00366-y","title":"A Practical Approach to Understanding Real-World Study Methodology in Cancer Research: A Vodcast","year":2025,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Advanced Causal Inference Techniques","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Pfizer","keywords":"Sample size determination; Research design; MEDLINE; Clinical Practice; Evidence-based medicine; Statistical analysis; Clinical trial; Statistical model","score_opus":0.8987679318139231,"score_gpt":0.6867908155549045,"score_spread":0.2119771162590186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414120871","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018455368,0.0033991605,0.9294416,0.05069567,0.005735468,0.0014364435,0.00040843975,0.001113893,0.0075848023],"genre_scores_gemma":[0.0038517846,0.0039016784,0.9594689,0.017813995,0.0036773968,0.0047806078,0.00035828186,0.0008310045,0.005316385],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.80621856,0.1625981,0.0125031015,0.00341313,0.014347117,0.00092002854],"domain_scores_gemma":[0.57279766,0.35389185,0.008143751,0.02624992,0.033897735,0.0050191097],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.20122963,0.0020401138,0.002090957,0.0071224975,0.0028975122,0.011066653,0.006169948,0.0063202106,0.027741004],"category_scores_gemma":[0.41033795,0.0024617151,0.002903093,0.005359355,0.011699629,0.012892723,0.015362463,0.020423688,0.015993875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010366061,0.000110377936,0.0008503595,0.0022171861,0.00010532347,0.00029278192,0.0023889374,0.0029755328,0.0004888096,0.32041076,0.38506278,0.28499362],"study_design_scores_gemma":[0.00011255026,0.0001829921,0.000382322,0.0035784387,0.000044955126,0.00080951187,0.0009277701,0.0063599763,0.00042678093,0.43723568,0.5498472,0.00009183606],"about_ca_topic_score_codex":0.0024172785,"about_ca_topic_score_gemma":0.0041666795,"teacher_disagreement_score":0.79877037,"about_ca_system_score_codex":0.0050461637,"about_ca_system_score_gemma":0.015877346,"threshold_uncertainty_score":0.98502606},"labels":[],"label_agreement":null},{"id":"W4417359965","doi":"10.1007/s40487-025-00406-7","title":"Social Determinants of Health in Metastatic Breast Cancer Care: A Podcast Exploring Challenges and Opportunities in the United States and Canada","year":2025,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Health care; Socioeconomic status; Health equity; Social determinants of health; Breast cancer; Ethnic group; Scope (computer science); Metastatic breast cancer; Scope of practice","score_opus":0.29897731773279473,"score_gpt":0.42306463785174125,"score_spread":0.12408732011894652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417359965","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02811502,0.2234354,0.0018710386,0.49057466,0.10455685,0.0009912327,0.030025668,0.0008199157,0.11961017],"genre_scores_gemma":[0.2142052,0.4532407,0.009717475,0.105307914,0.046790104,0.0010665498,0.017993515,0.00068013364,0.15099843],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.9991303,0.00012285619,0.000043530035,0.000051574232,0.00032536566,0.00032635452],"domain_scores_gemma":[0.9953171,0.0007334693,0.0001806862,0.00010173491,0.001470277,0.0021967376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022406774,0.00070873805,0.00077597087,0.0031065326,0.005107978,0.0050329776,0.0015527783,0.0025623145,0.018710772],"category_scores_gemma":[0.0039664353,0.00046915913,0.0010259598,0.0041598273,0.0014781941,0.0022910524,0.0041102828,0.0049427017,0.0016011159],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003198453,0.00006296238,0.002044943,0.00067965675,0.000015673671,0.00019863881,0.0013092371,0.00020778412,0.000097244934,0.0014729409,0.929739,0.06413988],"study_design_scores_gemma":[0.00005816455,0.00008328739,0.028747987,0.00492815,0.000047477275,0.000311088,0.010704865,0.00049056194,0.000113039365,0.0019579334,0.95246285,0.00009455842],"about_ca_topic_score_codex":0.88411176,"about_ca_topic_score_gemma":0.9706792,"teacher_disagreement_score":0.11588824,"about_ca_system_score_codex":0.026438206,"about_ca_system_score_gemma":0.06077267,"threshold_uncertainty_score":0.23314142},"labels":[],"label_agreement":null}]}